Maraviroc Solution

What This Maraviroc Shortage Record Means

The FDA Drug Shortages database lists this record for Maraviroc Solution (brand: SELZENTRY) from ViiV Healthcare Company with a current status of To Be Discontinued. The affected dosage form is Solution, presented as Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Jan 20, 2026 and was last updated Jan 20, 2026. The FDA cites the following reason: The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026. No other current shortage records match this generic in the database, which can signal that either the disruption is contained to one manufacturer or other suppliers have not yet formally reported a shortfall.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.